Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.

Vanderbilt researchers used single-cell sequencing, imaging, and computational approaches to characterize the colonic tumor microenvironment, providing important insights to the components that play roles in colorectal tumor pathogenesis.

Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.

Vanderbilt Wilson County Hospital's Lori Martin uses her own experiences to educate patients about the importance of early detection of colorectal cancer.